World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
45
Citations
7138
World Ranking
4714
National Ranking
2126

Jacquelyn A. Hank publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jacquelyn A. Hank sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 214 publications — 40th percentile

40% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Jacquelyn A. Hank D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jacquelyn A. Hank sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 45 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Jacquelyn A. Hank is affiliated with the University of Wisconsin-Madison in the United States. Their research primarily spans the fields of Medicine, Biochemistry, Genetics and Molecular Biology, and Immunology and Microbiology. Within these areas, they have contributed extensively to subfields including Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, Neurology, and Molecular Biology.

The scientist's work addresses several main research topics, which include:

  • Immunotherapy and Immune Responses
  • Neuroblastoma Research and Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Cancer therapeutics and mechanisms
  • Radiopharmaceutical Chemistry and Applications

Jacquelyn A. Hank has authored publications in multiple scientific journals and venues. The most frequent publication venues include:

  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Clinical Cancer Research

Recent papers authored or co-authored by Jacquelyn A. Hank feature a focus on immunotherapy and neuroblastoma and include the following:

  • Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032, 2021, Clinical Cancer Research
  • Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group, 2020, Journal of Clinical Oncology
  • Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group, 2022, Journal of Clinical Oncology
  • Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice, 2021, Journal for ImmunoTherapy of Cancer
  • Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models, 2021, Frontiers in Immunology

Frequent collaborators in Jacquelyn A. Hank's research include:

  • Paul M. Sondel
  • Amy K. Erbe
  • Zachary S. Morris
  • Alexander L. Rakhmilevich
  • Arika S. Feils

Best Publications

  • NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.

    Wei Wang;Amy K. Erbe;Jacquelyn A. Hank;Zachary S. Morris

  • Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

    Suzanne S. Shusterman;Wendy B. London;Stephen D. Gillies;Jacquelyn A. Hank

  • A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children’s Oncology Group

    Kaci L. Osenga;Jacquelyn A. Hank;Mark R. Albertini;Jacek Gan

  • A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.

    Jami D. Frost;Jami D. Frost;Jacquelyn A. Hank;Gregory H. Reaman;Sharon Frierdich

  • Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

    David M. King;Mark R. Albertini;Heidi Schalch;Jacquelyn A. Hank

  • Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

    Andrew L. Gilman;M. Fevzi Ozkaynak;Katherine K. Matthay;Mark Krailo

  • Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

    Jacquelyn A. Hank;Randy R. Robinson;Jean Surfus;Barbara M. Mueller

  • Human T lymphocyte clones reactive in primed lymphocyte typing and cytotoxicity

    Fritz H. Bach;Hiroo Inouye;Jacquelyn A. Hank;Barbara J. Alter

  • Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.

    Alice L. Yu;Alice L. Yu;Andrew L. Gilman;M. Fevzi Ozkaynak;Arlene Naranjo

  • Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

    David C. Delgado;Jacquelyn A. Hank;Jill Kolesar;David Lorentzen

  • Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

    Jeff A. Sosman;Peter C. Kohler;Jacquelyn Hank;Karen H. Moore

  • Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

    Paul M. Sondel;Peter C. Kohler;Jacquelyn A. Hank;Karen H. Moore

  • A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.

    Sara M. Federico;Sara M. Federico;M. Beth McCarville;Barry L. Shulkin;Paul M. Sondel

  • Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.

    Rajen Mody;Alice L Yu;Alice L Yu;Arlene Naranjo;Fan F Zhang

  • In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments

    Zachary S. Morris;Emily I. Guy;David M. Francis;Monica M. Gressett

  • Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

    Fariba Navid;Paul M. Sondel;Raymond Barfield;Barry L. Shulkin

  • Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.

    P M Sondel;J A Hank;P C Kohler;B P Chen

  • TCGF production for cloning and growth of functional human T lymphocytes.

    H. Inouye;J. A. Hank;B. J. Alter;F. H. Bach

  • Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.

    Zane C. Neal;Jeannie C. Yang;Alexander L. Rakhmilevich;Ilia N. Buhtoiarov

  • Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial.

    D M Mahvi;M B Henry;M R Albertini;S Weber

  • Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

    Jacquelyn A. Hank;Jean E. Surfus;Jacek Gan;Peter Jaeger

  • Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

    Jeff A. Sosman;Peter C. Kohler;Jacquelyn A. Hank;Karen H. Moore

  • Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.

    Jean E. Surfus;Jacquelyn A. Hank;Egbert Oosterwijk;Sydney Welt

Frequent Co-Authors

Paul M. Sondel
Paul M. Sondel University of Wisconsin–Madison
Stephen D. Gillies
Stephen D. Gillies MSD (United States)
Ralph A. Reisfeld
Ralph A. Reisfeld Scripps Research Institute
Paul M. Sondel
Paul M. Sondel University of Wisconsin–Madison
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Alice L. Yu
Alice L. Yu University of California, San Diego
Wendy B. London
Wendy B. London Harvard University
John M. Maris
John M. Maris Children's Hospital of Philadelphia
Joan H. Schiller
Joan H. Schiller University of Virginia
Alan J. Korman
Alan J. Korman VIR Biotechnology (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can expand career options. Nursing professions, in particular, often intersect with immunological knowledge. If you're starting your nursing journey, consider programs that are accessible and efficient. For example, the fastest and easiest LPN programs provide a quick pathway into practical nursing roles, laying a strong foundation for advanced studies.

As you advance, selecting the right graduate program is crucial. The which nurse practitioner program is easiest guide helps identify programs that balance rigor with support, ideal for professionals juggling work and study.

Mental health is another critical area closely tied to immunological research. Programs like the top online PMHNP programs emphasize clinical placements, ensuring hands-on experience in psychiatric mental health nursing.

For budget-conscious students, the cheapest online PMHNP programs offer quality education without the high costs, making advanced nursing degrees more accessible. Together, these options provide diverse pathways aligned with immunology-related careers.

Best Scientists Citing Jacquelyn A. Hank

Trending Scientists

Recently Published Articles